Investment Thesis
Schrodinger is a cash-burning biotech company with zero revenue growth, deteriorating operational losses reaching -83.3% margin, and negative free cash flow of -$17.3M annually. While the company maintains a fortress balance sheet with $260M cash and no debt, the flat-lined business lacks commercialization traction and shows no clear path to operational profitability.
Strengths
- Fortress balance sheet with $260.3M cash reserves and zero debt, providing 15-year cash runway
- Healthy gross margins of 50.4% demonstrate viable product economics at the unit level
- Excellent liquidity metrics (2.74x current ratio) ensuring near-term financial flexibility
Risks
- Negative free cash flow of -$17.3M annually with no improvement trajectory despite substantial cash reserves
- Revenue completely stalled at $58.6M with 0% YoY growth indicating failed commercialization momentum
- Unsustainable cost structure with operating losses of -$48.8M (-83.3% margin) that exceed gross profit generation
Key Metrics to Watch
- Revenue growth acceleration from 0% to establish market traction and product demand
- Operating cash flow inflection from negative to positive demonstrating path to breakeven
- Operating margin improvement toward breakeven as revenue scales or cost structure optimizes
Financial Metrics
Revenue
58.6M
Net Income
-60.0M
EPS (Diluted)
$-0.81
Free Cash Flow
-17.3M
Total Assets
634.2M
Cash
260.3M
Profitability Ratios
Gross Margin
50.4%
Operating Margin
-83.3%
Net Margin
-102.5%
ROE
-19.1%
ROA
-9.5%
FCF Margin
-29.6%
Balance Sheet & Liquidity
Current Ratio
2.74x
Quick Ratio
2.74x
Debt/Equity
0.00x
Debt/Assets
50.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:28:41.970242 |
Data as of: 2026-03-31 |
Powered by Claude AI